apelin-F13A

Apelin-F13A is a synthetic peptide that acts as a potent antagonist of the apelin receptor (APLNR, also known as APJ). It is a modified version of the endogenous peptide fragment apelin-13, in which the C-terminal phenylalanine (Phe) at position 13 is substituted with alanine (Ala). This specific modification converts the peptide from an agonist into a functional antagonist. In preclinical research, particularly in glioblastoma (GBM) models, Apelin-F13A has been shown to inhibit tumor-induced neo-vascularization, promote vascular normalization, and reduce vasogenic edema. By blocking apelin signaling, it may also mitigate the invasive side effects and improve the efficacy of standard anti-angiogenic therapies, such as VEGF inhibitors.

Other names

[Ala13]apelin-13F13A-apelin-13F-13A-apelin-13F 13A-apelin-13Phe13Ala-apelin-13Phe-13Ala-apelin-13Phe 13Ala-apelin-13